Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.

Eli Lilly and Company today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatrutide, eloralintide and bimagrumab will be presented at ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Arrowhead Pharmaceuticals, Inc.'s deal with Sarepta expands its pipeline, but limited plozasiran market and competition ...

Because Lilly doesn’t offer all of its Zepbound doses through Lilly Direct, she’s had to lower her dose from 15 milligrams to 10 mg. She has also found the process of drawing the medication up ...

"We are introducing Wegovy (injectable Semaglutide 2.4 mg) this year, which offers full therapeutic strengths of semaglutide ...

Strengths are listed in milligrams per milliliter (mg/mL). Your doctor will show you or a caregiver how to inject Zepbound or Wegovy. You inject either drug under the skin of your abdomen ...

Zepbound is a weekly injectable prescription ... to support long-term weight loss offers one-on-one coaching offers a 10% weight loss money-back guarantee navigates insurance coverage of GLP ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy.

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli Lilly’s popular weight loss medication Zepbound and diabetes drug Mounjaro.

Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that ... West is coming to San Francisco! (July 8-10, 2025).